Document:

Exhibit 10.47

 

AMENDMENT TO EMPLOYMENT AGREEMENT

BY AND BETWEEN PROTEONOMIX, INC. AND MICHAEL COHEN

This amended agreement (the “Agreement”) is made as of this 21ST day of December, 2009, to an employment agreement originally executed on January 5, 2005, as restated January 4, 2008, and amended July 1, 2009 (the “Employment Agreement”) by and between Proteonomix, Inc. formerly National Stem Cell Holding, Inc., a Delaware corporation (the “Company”) with an address a 187 Mill Lane, Mountainside, New Jersey 07092 and Michael Cohen, with an address at7 Stanford Court, West Orange, New Jersey 07052 (the Employee”) (the parties hereto are herein referred to as the “Parties”).

WHEREAS, the Agreement as amended and restated failed to address milestones and milestone payments to the Employee which were agreed upon orally between the Employee and the Company; and

WHEREAS, the Parties desire to reflect milestones and milestone payments to the Employee in a written agreement.

NOW, THEREFORE, in consideration of the mutual covenants herein set forth the Employment Agreement is hereby amended as follows: 

1.

The Company hereby memorializes bonus milestones for the Employee as follows:

a.

 positive cash flow for the Company as a whole (including subsidiaries) on a calendar quarter basis;

b.

 the Company’s or its subsidiaries’ patents becoming effective; 

c.

FDA approval of any of the Company’s technologies for Phase I, II and III;

d.

 sales of cosmeceuticals by the Company’s subsidiary Proteoderm, and

e.

Proteoderm becoming a public company. 

2.

The Additional milestones may be adopted by the Board of Directors from time to time.

3.

Clauses in the Employment Agreement not affected by the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first above written.

PROTEONOMIX, INC.

/s/ Michael Cohen

/s/ Joel Pensley

Michael Cohen

Joel Pensley, SecretaryExhibit 10.48

                               Research Agreement
                            The University of Miami

This  Research  Agreement (the "Agreement") is entered into as of this 1/31/2008
(the "Effective Date"),  by and between The University of Miami, located at 1507
Levante Avenue, Coral Gables,  Florida  33124  (the "Institution"), and National
Stem Cell, a corporation organized under the laws  of  the  State  of a Delaware
having an address at 1130 Route 22 West, Mountainside, NJ (the "Sponsor").

WHEREAS,  Sponsor wishes that Institution conduct research studies as  described
in the Statement of Work, attached hereto as Exhibit A.

NOW, THEREFORE,  in  consideration  of the following mutual promises, covenants,
and conditions and any sums to be paid, the parties hereto agree as follows:

1.    STATEMENT OF WORK

The Institution agrees to conduct in  collaboration  with  Sponsor  the research
studies  entitled: Ex Vivo Expansion of Cord Blood Cells (Research Project),  as
described  in  the Statement of Work for this study (attached as Exhibit A). The
Institution represents  that to the best of its knowledge that it has, or by the
commencement of the Research  Project will have, the experience, capability, and
resources, including, but not limited to, sufficient personnel and equipment, to
efficiently and expeditiously perform the Research Project in a professional and
competent  manner,  and  in  strict   adherence  to  the  protocol.  Institution
represents and warrants that it will use  reasonable  efforts to ensure that the
Research  Project  will  be  in  accordance with all federal,  state  and  local
regulatory laws, rules and practices.  Sponsor  is  providing certain technology
and biological materials for the Study. Investigator shall not co-mingle funding
that might incur obligations to third parties; and shall not co-mingle materials
of  the  study  or  of  Sponsor with those of third parties  which  might  incur
obligations to third parties.

2.    INVESTIGATOR

This Research Project will  be conducted under the direction of Ian McNiece, PhD
(the "Investigator"). The Investigator  shall be responsible for performing this
Research  Project  and  for  direct supervision  of  any  individual  performing
portions of this study. In the  event  the  Investigator  becomes  unwilling  or
unable  to  perform the duties required for the Research Project conducted under
this Agreement, the Institution and Sponsor shall attempt to agree on a mutually
agreeable replacement.  In  the  event  a mutually acceptable replacement is not
available, then the Research Project may be terminated by either party hereto in
accordance with Section 8 of this Agreement.

3.    PAYMENT

(a)   In consideration of conducting the  Research  Project  hereunder,  Sponsor
shall  pay  Institution  in accordance with the budget attached as Exhibit B  of
this Agreement. The Direct  Costs  shown  in Exhibit B are subject to University
Indirect Costs of $23,612 for a total payment of $118,060.

Payments shall be made as follows: 50% of the  budget will be due within 90 days
of the execution of this agreement, 25% will be  due  on the completion date and
the final 25% due upon delivery of the final report.

(b)   Payments shall be addressed to the University's central  lockbox  account,
referencing the Contract No. and the Investigator.

      Payable to: The University of Miami Tax I.D. Number.
      University of Miami
      Sponsored Programs
      P.O. Box 025405
      Miami, FL 33102-5405

The  check  should indicate the University account number. A copy of the payment
transmittal shall be sent to the Principal Investigator

<PAGE>1

It is expected  that grant funds will be expended in general accordance with the
budget attached as  Exhibit B. Actual expenditures may vary at the discretion of
the University.

4.    RECORDKEEPING, REPORTING, ACCESS

Authorized representatives  of  Sponsor or its designee shall have the right, at
mutually agreed upon times, and during  regular  business  hours, to examine and
inspect the Institution's and applicable Investigator's facilities  and  records
associated  with  this  Study  and  inspect  records  relating  to this Research
Project.

Institution shall advise Sponsor of the results of the Research Project at least
once  in  every two-week period during the term of this Agreement,  and  provide
Sponsor with  semi-annual  informal  written  progress  reports  concerning  the
details  of the progress of the Research Project. A final written report setting
forth the results achieved under and pursuant to the Research Project, including
the Study  Results  and the Subject Inventions, shall be submitted by to Sponsor
within thirty (30) days  of  the  completion  of  the  Research  Project  or the
termination  of  this  Agreement,  whichever is earlier. Such final report shall
include, but may not be limited to, a complete summary of the activities carried
out,  including:  design details, prototypes,  testing  protocols  and  detailed
results.

5.    PROPRIETARY INFORMATION AND CONFIDENTIALITY

Neither party shall  disclose  to  any third party or use for any purposes other
than the performance of this Research  Project,  any and all compositions, data,
information, materials, methods, processes, trade  secrets,  privileged records,
or  other  proprietary  information  disclosed to one party by the  other  party
pursuant to this Agreement (collectively,  "Proprietary  Information"),  without
providing  the  party's prior written consent, except as otherwise specified  in
this Agreement. The  receiving  party shall treat the Proprietary Information as
it would treat its own proprietary  information,  but  in  no event shall it use
less than a reasonable degree of care. The obligation of non-disclosure and non-
use shall not apply to the following.

(a)   Information,  which  at  the  time of disclosure hereunder,  is  generally
available to the public;

(b)   Information, which after disclosure hereunder, becomes generally available
to the public, except through breach of this Agreement;

(c)   Information that a party can demonstrate was in its possession at the time
of  disclosure  by  the other party and  that  was  not  acquired,  directly  or
indirectly, from such other party;

(d)   Information that  becomes  available to a party from a third party that is
not  legally  prohibited  from  disclosing   such   information,  provided  such
information  was  not  acquired  directly or indirectly from  a  party  to  this
agreement

(e)   Information that is independently  developed  by a party without reference
to the Proprietary Information, as documented by written evidence; or

(f)   Information  required by any law, regulation, or  order  of  court  to  be
disclosed. Prior to  disclosing  proprietary  or confidential information of the
other party, the disclosing party shall first notify  the  providing  party  and
provide it an opportunity to prevent disclosure if practicable.

In  addition,  the terms of this Agreement supersede any previous non-disclosure
agreements or any  other preliminary representations or understandings that have
been entered into by  the  parties  to this Agreement with regard to the subject
Research Project.

The obligations of nonuse and confidentiality  set forth herein shall extend for
a period of five (5) years from the date of disclosure.

<PAGE>2

6.    RESULTS AND INTELLECTUAL PROPERTY

Any  and  all  study data, information, inventions,  compositions,  discoveries,
materials, methods,  processes,  and/or  technology generated by performing this
Research Project, including all study results  ("Study  Results") as well as all
potentially patentable results, information, ideas, inventions,  developments or
discoveries  first  conceived  and/or  reduced  to  practice  in  the course  of
performance  of  this  Agreement  ("Subject  Inventions") shall be the sole  and
exclusive property of the Sponsor. Sponsor and the Investigator hereby delivers,
assigns,  and  will  deliver  and  assign  the Study  Results  and  the  Subject
Inventions and all of its rights, title and interest in and to the Study

2

Results and the Subject Inventions to Sponsor  and  agrees  to  execute and have
executed by relevant personnel and individuals all oaths, assignments, and other
relevant documentation (at Sponsor's reasonable expense) reasonably necessary to
effect the transfer of ownership contemplated under this Section.

7.    PUBLICATION

The Institution and the Investigator are free to publish, present,  or  use  any
results  arising  out  of  this  Research  Project  for their own instructional,
research,  or publication objectives, provided that such  publication  does  not
disclose any of Sponsor's Proprietary Information, as defined in this Agreement.
Institution agrees to submit the draft of any proposed publication to Sponsor at
least sixty  (60)  days  prior  to submission for publication, presentation, and
agrees, at the request of Sponsor,  to  withhold  any  such  submission  for  an
additional  period,  not  to  exceed sixty (60) days in order to file any patent
applications at the request of Sponsor.

8.    TERM AND TERMINATION

(a)   Unless earlier terminated  in  accordance  with  the  provisions  of  this
Agreement,  the  term of this agreement shall commence on the Effective Date and
shall terminate six  months  after  the  Effective  Date.  This Agreement may be
terminated by Sponsor or institution upon at least sixty (60) days prior written
notice to the other party.

(b)   In  addition,  the  Agreement  may be terminated by either  party  if  the
Investigator conducting the Research Project  is unwilling or unable to continue
performing  the study and a successor to both Sponsor  and  Institution  is  not
available.

If this Agreement  is  terminated  prior  to  the  original termination date and
Sponsor has not yet remitted the full estimated project  total  to  Institution,
Sponsor  shall  still  be  held  responsible  for all non-cancelable Institution
expenses and shall remit such total within thirty  (30)  days  of  Institution's
written request for final payment.

Sections  4,  5, 6, 9, 10 and ii of this Agreement shall survive any termination
or expiration of this Agreement.

9. WARRANTIES

UNIVERSITY MAKES NO WARRANTIES, EXPRESS OR IMPLIED AND HEREBY DISCLAIMS ALL SUCH
WARRANTIES DEVELOPED UNDER THIS AGREEMENT; OR THE OWNERSHIP, MERCHANTABILITY, OR
FITNESS FOR A PARTICULAR  PURPOSE  OF  THE  RESEARCH  OR  ANY  SUCH INVENTION OR
PRODUCT. UNIVERSITY SHALL NOT BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL,  OR OTHER
DAMAGES SUFFERED BY ANY LICENSEE OR ANY THIRD PARTIES RESULTING FROM THE  USE OF
THE RESEARCH OR ANY SUCH INVENTION OR PRODUCT.

The  provision  of  this paragraph shall continue beyond the termination of this
Agreement

10.   INDEMNIFICATION

Sponsor  agrees  to  release,   indemnify   and   hold  harmless  the  Principal
Investigator,  University,  its  Trustees,  officers,  faculty,   employees  and
students  (University)  against  any and all losses, expenses, claims,  damages,
actions, lawsuits and judgments thereon  (including  attorney  fees  through the
appellate levels), which may be brought against the University, arising  out  of
or reasonably attributable to 1) the activities to be carried out in this

<PAGE>3

research and development study, 2) any negligent act or omission of Sponsor, its
agents  or  employees or any product or equipment supplied by Sponsor, or 3) the
use, possession  or operation by the Sponsor or any third party of any Invention
or Discovery developed under this Agreement.

Sponsor, its agents  and employees agree to release, hold harmless and indemnify
the University from and  against any and all loss, claims, or damages, including
bodily injury or death or property damage, and including attorney fees, suffered
by Sponsor, and its agents  and  employees  while  on  the  University premises,
provided  that  such  loss,  claim  or  damage does not arise out of  University
negligence.

Except as otherwise provided in this Agreement,  University  agrees  to release,
indemnify  and hold harmless Sponsor, its officers, directors and employees  for
any and all  losses,  expenses, claims, damages, actions, lawsuits and judgments
therein (including attorney  fees  through  the  appellate  levels) which may be
brought against

Sponsor, its officers, directors and employees arising out of  any negligent act
or omission of University, its faculty, employees or agents.

In  the  event  any such claim is made or lawsuit is initiated, the  persons  or
party against whom  such  lawsuit  is  brought  or  claim is made shall promptly
notify the other party in writing, and shall cooperate  fully  in the defense of
such  lawsuit  and  permit  the indemnifying party or its insurance  carrier  to
defend such a claim or lawsuit.

The provisions of this paragraph  shall  continue beyond the termination of this
Agreement.

11.   INSURANCE

Sponsor and University each agree to carry  and  keep  in  force,  each  at  its
expense,  general  liability  insurance with limits not less than $1,000,000 per
person and $3,000,000 aggregate  to  cover  liability  for damages on account of
bodily or personal injury or death to any person, or damage  to  property of any
person. Sponsor shall keep in force product liability insurance with  limits not
less  than  $5,000,000  prior  to  commencement  of  human subject testing. Such
insurance shall not be cancelled for any cause without  at  least  30 days prior
written  notice  to  the  other  party.  Such  cancellation  shall be cause  for
termination.

Sponsor's  insurance  shall contain an endorsement naming the University  as  an
additional insured with  respect  to  this  Agreement  Sponsor  shall  provide a
certificate of insurance or a self-insurance letter (if Sponsor is self-insured)
stating the limits of coverage. Such insurance shall be written to cover  claims
incurred, discovered, manifested or made during or after the expiration of  this
Agreement.  Insurance  Certificates  should  be sent to the University of Miami,
attention  Dr.  Gary Margules, Director, Office  of  Technology  Transfer,  1475
Northwest 12th Avenue, Room 2012, Miami, Florida 33136.

12.   FEDERAL REGULATIONS

No human subject  testing  shall  be conducted under this Agreement. Any studies
involving the use of vertebrate animals  shall comply with all state and federal
statutes, rules and regulations governing  animal  care  and  use.  Any  studies
involving  isotopes  must  comply  with any and all applicable state and federal
rules, regulations and statutes. Recombinant  DNA research shall be performed in
accordance  with regulations promulgated as Guidelines  for  Research  Involving
Recombinant DNA  Molecules, U.S. Department of Health and Human Services, Public
Health Service, National Institutes of Health.

<PAGE>4

13.   NOTICES

With the exception  of study funds paid by Sponsor pursuant to Section 3 hereof,
all notices required  or  permitted to be given under this Agreement shall be in
writing and shall be sent as follows:

If to Sponsor: National Stem Cell
187 Mill Lane Mountainside, NJ Attn: Michael Cohen
Chief Executive Officer

With a copy to:

Pearl Cohen Zedek Latzer, LLP
10  Rockefeller  Plaza,
Suite 1001 New York, New
York, 10020 Telephone 212-632-3494
Facsimile 212-632-3489
Attn: Mark S. Cohen

If to Institution:

Ms. Aida Diaz-Piedra
Controller
Office of Controller
212 Max Orovitz Bldg.
1507 Levante Avenue
Coral Gables, FL 33124-1422

Mr. Alan J. Fish
Vice President
Business Services
327 Max Orovitz Bldg.
1507 Levante Avenue
Coral Gables, FL 33124-1432

Dr.  Richard  Bookman
Vice Provost for Research
P.O. Box 016960  (R-64)
Miami,Florida 33101

Copy to: Investigator

14.   INDEPENDENT CONTRACTORS

The relationship of Sponsor to Institution and its Investigator shall be that of
an Independent Contractor and none of the parties shall hold itself out to third
parties as purporting to act as, or on behalf of, the other party hereto.

15.   USE OF OTHER PARTIES' NAMES

Neither the Sponsor nor the Institution shall use directly or by implication the
names  of  the  other  party,  nor  any  of  the  other  party's  affiliates  or
contractors, nor any abbreviations  thereof,  or  of  any  staff member, faculty
member, student, or employee of the other party in connection with any products,
promotion,  advertising,  or other public disclosure without the  prior  written
permission of the other party.  Sponsor  is  permitted to state that Sponsor has
entered into a Research Agreement with Institution,  for  factual  purposes, but
not for marketing or promotion purposes. The Institution herby acknowledges that
the Sponsor is allowed to disclose this agreement to potential investors without
any  further  notification to the Institution. The Sponsor agrees to notify  and
request the permission  of  the  Institution  prior  to  the  use  of  its name,
employees name or its affiliates name prior to any publication that the  Sponsor
may publish. The institution shall respond to the Sponsors notification within 5
business days. Institution may use Sponsor's name in its Research Notes.

<PAGE>5

16.   WAIVERS; SEVERABILITY

No  waiver  of  any  term  or  provision of this Agreement whether by conduct or
otherwise in any one or more instances shall be deemed to be, or construed as, a
further or continuing waiver of any such term or provision, or of any other term
or provision, of this Agreement.

17.   CONTINUING OBLIGATION

Except as otherwise specifically  provided herein, termination of this Agreement
shall not relieve either party hereto  from  any obligation under this Agreement
that accrued or arose from facts or circumstances in existence prior thereto.

18. ASSIGNMENT.

This Agreement shall be binding upon and shall  inure  to  the  benefits  of the
parties  hereto  and  the  successors  to  substantially the entire business and
assets of the respective parties hereto. This  Agreement shall not be assignable
by either party without the prior written consent of the other party.

19.   ENTIRE AGREEMENT

This Agreement embodies the entire understanding  between  Institution  and  the
Sponsor  for  or this project, and any prior or contemporaneous representations,
either oral or  written, are hereby superseded. No amendments or changes to this
Agreement, including without limitation, changes in the statement of work, total
cost, and period  of  performance, shall be effective unless made in writing and
signed by authorized representatives of the parties.

20.   HEADINGS

The headings in this Agreement are for the convenience of reference only and are
not  substantive  parts  of   this   Agreement   nor   shall   they  affect  its
interpretation.

21.   COUNTERPARTS

This Agreement and any amendments hereto may be executed in counterparts and all
such counterparts taken together shall be deemed to constitute one  and the same
instrument.

In  Witness  Whereof,  the parties have caused this Agreement to be executed  by
their duly authorized representatives as of the Effective Date.

NATIONAL STEM CELL, INC

By: /s/Michael Cohen
---------------------
MichaeI Cohen
Chief Executive Officer

Date: 11/20/07

THE UNIVERSITY OF MIAMI

By: /s/ Tom Gill
-----------------
TOM GILL
DIRECTOR OF RESEARCH

Date:

Read and Agreed to:

/s/ Ian McNiece
----------------
Investigator

<PAGE>6

                                   EXHIBIT A

                                 SCOPE OF WORK

Cord Blood (CB) products  have  become  a  standard  hematopoietic cell graft as
support  for  cancer  patients undergoing high dose chemotherapy.  However,  the
number of cells available  in a CB product is limited and the use of CB products
for adult patients has been  limited.  Therefore  a number of Investigators have
explored ex vivo expansion of CB products as a means  to  provide increased cell
numbers. The research to be undertaken in this project will  evaluate approaches
for  isolation  of  subpopulations of hematopoietic cells from CB  products  for
optimal expansion of total nucleated cells.

In previous research  studies  McNiece  and colleagues have demonstrated that ex
vivo culture of CB mononuclear cells (MNC) results in minimal expansion of total
cells.  This  led  to the use of CD34 selection  of  CB  products,  however,  in
clinical trials where  frozen  CB  products  were required the recovery of CD34+
cells and the purity of the final selected cells  was  highly variable resulting
in minimal efficacy. In further studies we have identified  selection approaches
that  result  in  passive removal of "inhibitor)," cells from the  MNC  enabling
optimal recovery of  CD34+  cells  and  providing  a cell population that can be
effectively expanded in culture.

The goal of this research is to evaluate the preparation  of  CB  products using
rosette  technology  which  will generate a starting cell population capable  of
optimal expansion in culture.  We  will perform separation of 10 CB products and
identify  the  optimal  processing procedure.  These  experiments  will  compare
different antibody to cell  ratios  and  different  cell  concentrations  of the
labeled  cells  on  density gradient separation. Subsequently the separated cell
populations will be expanded  for  14  to  21  day  periods  and  evaluated  for
expansion  of  various  cell  populations including CD34+ cells, total nucleated
cells, myeloid progenitor cells  (GM-CFC)  and  primitive progenitor cells (HPP-
CFC).

GOAL OF STUDIES:

The minimal cell dose required for transplantation  of  CB  products  is 1 x 107
TNC/kg, we will target a minimal cell increase of 5 fold which would result in a
cell  dose  of  expanded  cells  of  5 x 107 TNC/kg. Ideally, a level of 10 fold
expansion would be desired to account  for  CB  products with an even lower cell
dose of around 5 x 106 TNC/kg, therefore also resulting  a  cell dose of 5 x 107
TNC/kg. Therefore the goal of these studies is to determine if a reproducible ex
vivo expansion of at least 5 fold can be achieved with an optima/result being
10 fold expansion.

<PAGE>7

                                   EXHIBIT B
<table>
<c>                                                                  

                           BUDGET FOR STUDY
                DETAILED BUDGET FOR INITIAL BUDGET PERIOD
                            DIRECT COSTS ONLY
PERSONNEL (Applicant organization only)%
                                                        FROM         THROUGH
                                                        01/01/08     06/30/08
                                                       DOLLAR AMOUNT REQUESTED
                                                              (omit cents)
---------------------------------------------------------------------------------------------
                       ROLE ON        TYPEE    FFORT      INST.
                       PROJECT         APPT.    ON        BASE     SALARY     FRINGE
NAME                                 (months)  PROJ.     SALARY   REQUESTED  BENEFITS  TOTAL
----------------------------------------------------------------------------------------------
Ian McNiece, PhD      Principal          12     10%       350,000   17,500    4,848    22,348
TBD                   Technician         12    100%       40,000    20,000    6,840    26,840

SUBTOTALS                                                           37,500    11,688   49,188

CONSULTANT COSTS                                                                            0

EQUIPMENT (Itemize)                                                                         0

SUPPLIES (Itemize by category)
Ficoll, buffers, FCS: $3,000
Plastic disposables for tissue culture $5,000
Antibodies $7,500
Selection reagents $10,000
Growth Factors $10,000
Methylcellulose $3,000
------------------------------
                                                                                      $38,500

TRAVEL                                                                                      0

PATIENT CARE COSTSI INPATIENT                                                               0
                    OUTPATIENT                                                              0

ALTERATIONS AND RENOVATIONS (Itemize by category)                                           0

OTHER EXPENSES (Itemize by category)
  FACS analysis ($65/hr x 4 his per week x 26 weeks) $6,760                            $6,760

SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD                                       $94,448

CONSORTIUM/CONTRACT        DIRECT COSTS

TOTAL

COSTS                    FACILITIES AND ADMINISTRATIVE COSTS

TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 7a, Face Page)                     $94,448

                                                       Indirect costs                 $23,612
                                                                                     ---------
                                                       Grand Total                   $118,060
                                                                                     =========
<PAGE>8

</table>

PROTEONOMIX
187 Mill Lane
Mountainside, NJ 07092

February 12, 2009

Tom Gill
Director of Administration University of Miami
212 Max Orvitz Building
1507 Levante Avenue
Coral Gables, FL 33124-1422

Re:  Sponsored  Research  agreement by National Stem Cell Holding, Inc. (renamed
Proteonomix, Inc.)

Dear Mr. Gill,

Enclosed please find a copy  of  sponsored research agreement to be conducted at
the University of Miami. Please be advised that National Stem Cell Holding, Inc.
has changed its name to Proteonomix,  Inc.  (the "Company") but continues as the
same  corporate entity. Further, because of corporate  constraints  the  Company
could not  effectuate  the research agreement in 2008 but would like to initiate
the research as soon as possible.

The Company would like to amend the agreement as follows:

a) New effective date - February 9, 2009

b) Name on the agreement - Proteonomix, Inc.

c) Address of the Company - 187 Mill Lane, Mountainside, NJ 07092

d) Telephone and fax numbers - phone 973-544-6116 and fax 973-833-0277

e) Copy notice to Joel Pensley Attorney at Law, 211 Schoolhouse Road, Norfolk CT
06058 phone: 860-542-1122 fax 212-898-1266 email: jpensley@gmail.com'

The Company respectfully  requests  this  letter  constitute an amendment to the
existing agreement as of the date above. Please review and accept this letter at
your convenience.

Thank you in advance for your assistance with this  matter.  If  you should have
any questions or requests, please feel free to contact me anytime.

Sincerely,

Accepted:

Proteonomix, Inc.                    University of Miami

/s/Michael Cohen CEO                 /s/Mr. Tom Gill
--------------------                 -------------------------
                                     Director of Administration

<PAGE>8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]